Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290364 | 0.92 | MMP8 (0.54) | MMP8CTSAALDH1A1MAPTNPSR1 | |
| SCHEMBL29824513 | 0.92 | MMP8 (0.54) | MMP8CTSAALDH1A1MAPTNPSR1 | |
| SCHEMBL29841550 | 0.88 | MMP8 (0.54) | MMP8CTSAALDH1A1MAPTHPGD | |
| SCHEMBL14254979 | 0.88 | MMP8 (0.54) | MMP8CTSAALDH1A1MAPTHPGD | |
| SCHEMBL27758476 | 0.87 | MMP8 (0.49) | MMP8CTSAALDH1A1MAPTNPSR1 | |
| SCHEMBL4162223 | 0.85 | MMP8 (0.48) | MMP8CTSAALDH1A1MAPTNPSR1 | |
| SCHEMBL22242513 | 0.84 | MMP8 (0.47) | MMP8CTSAALDH1A1MAPTNPSR1 | |
| SCHEMBL290365 | 0.83 | ALDH1A1 (0.43) | MMP8CTSAALDH1A1MAPTNPSR1 | |
| SCHEMBL1275691 | 0.82 | MMP8 (0.70) | MMP8CA12CA1CA2CA9 | |
| SCHEMBL5856096 | 0.82 | SRC (0.58) | CTSAALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102438975-A | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC BIOSCIENCES INC | 2012-05-02 | — | — | CN | disclosed |
| EP-2190833-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | Novartis Ag (CH) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009024615-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BRIARD EMMANUELLE | 2009-02-26 | — | — | US | disclosed |
| US-3985779-A | ANTIINFLAMMATORY AND ANALGESIC ACTIVITIES | EISAI CO., LTD. (JA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054427-A1 | AMINOBENZYL-SUBSTITUTED CYCLIC SULFONES USEFUL AS BACE INHIBITORS | BACE2, BACE1, APP | MMP8 1876/4885CTSA 170/4885ALDH1A1 2720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.